Literature DB >> 31813991

LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks.

Katharina A Schindlbeck1, An Vo1, Nha Nguyen2, Chris C Tang1, Martin Niethammer1, Vijay Dhawan1, Vicky Brandt1, Rachel Saunders-Pullman3, Susan B Bressman3, David Eidelberg1.   

Abstract

The natural history of idiopathic Parkinson's disease (PD) varies considerably across patients. While PD is generally sporadic, there are known genetic influences: the two most common, mutations in the LRRK2 or GBA1 gene, are associated with slower and more aggressive progression, respectively. Here, we applied graph theory to metabolic brain imaging to understand the effects of genotype on the organization of previously established PD-specific networks. We found that closely matched PD patient groups with the LRRK2-G2019S mutation (PD-LRRK2) or GBA1 variants (PD-GBA) expressed the same disease networks as sporadic disease (sPD), but PD-LRRK2 and PD-GBA patients exhibited abnormal increases in network connectivity that were not present in sPD. Using a community detection strategy, we found that the location and modular distribution of these connections differed strikingly across genotypes. In PD-LRRK2, connections were gained within the network core, with the formation of distinct functional pathways linking the cerebellum and putamen. In PD-GBA, by contrast, the majority of functional connections were formed outside the core, involving corticocortical pathways at the network periphery. Strategically localized connections within the core in PD-LRRK2 may maintain PD network activity at lower levels than in PD-GBA, resulting in a less aggressive clinical course.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.

Entities:  

Keywords:  zzm321990 GBAzzm321990 ; zzm321990 LRRK2zzm321990 ; Parkinson’s disease; functional connectivity; metabolic imaging

Year:  2020        PMID: 31813991      PMCID: PMC7197067          DOI: 10.1093/cercor/bhz280

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  50 in total

1.  Complex network measures of brain connectivity: uses and interpretations.

Authors:  Mikail Rubinov; Olaf Sporns
Journal:  Neuroimage       Date:  2009-10-09       Impact factor: 6.556

2.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Authors:  E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

3.  Glucose utilization: still in the synapse.

Authors:  A Jon Stoessl
Journal:  Nat Neurosci       Date:  2017-02-23       Impact factor: 24.884

4.  Beyond modularity: Fine-scale mechanisms and rules for brain network reconfiguration.

Authors:  Ankit N Khambhati; Marcelo G Mattar; Nicholas F Wymbs; Scott T Grafton; Danielle S Bassett
Journal:  Neuroimage       Date:  2017-11-11       Impact factor: 6.556

5.  Progression in the LRRK2-Asssociated Parkinson Disease Population.

Authors:  Rachel Saunders-Pullman; Anat Mirelman; Roy N Alcalay; Cuiling Wang; Roberto A Ortega; Deborah Raymond; Helen Mejia-Santana; Martha Orbe-Reilly; Brooke A Johannes; Avner Thaler; Laurie Ozelius; Avi Orr-Urtreger; Karen S Marder; Nir Giladi; Susan B Bressman
Journal:  JAMA Neurol       Date:  2018-03-01       Impact factor: 18.302

6.  Scaled subprofile modeling of resting state imaging data in Parkinson's disease: methodological issues.

Authors:  Phoebe G Spetsieris; David Eidelberg
Journal:  Neuroimage       Date:  2010-10-20       Impact factor: 6.556

Review 7.  Building better biomarkers: brain models in translational neuroimaging.

Authors:  Choong-Wan Woo; Luke J Chang; Martin A Lindquist; Tor D Wager
Journal:  Nat Neurosci       Date:  2017-02-23       Impact factor: 24.884

8.  Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity.

Authors:  Martin Niethammer; Chris C Tang; An Vo; Nha Nguyen; Phoebe Spetsieris; Vijay Dhawan; Yilong Ma; Michael Small; Andrew Feigin; Matthew J During; Michael G Kaplitt; David Eidelberg
Journal:  Sci Transl Med       Date:  2018-11-28       Impact factor: 17.956

9.  Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease.

Authors:  Chris C Tang; Kathleen L Poston; Vijay Dhawan; David Eidelberg
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

10.  The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.

Authors:  Shu-Ying Liu; Daryl J Wile; Jessie Fanglu Fu; Jason Valerio; Elham Shahinfard; Siobhan McCormick; Rostom Mabrouk; Nasim Vafai; Jess McKenzie; Nicole Neilson; Alexandra Perez-Soriano; Julieta E Arena; Mariya Cherkasova; Piu Chan; Jing Zhang; Cyrus P Zabetian; Jan O Aasly; Zbigniew K Wszolek; Martin J McKeown; Michael J Adam; Thomas J Ruth; Michael Schulzer; Vesna Sossi; A Jon Stoessl
Journal:  Lancet Neurol       Date:  2018-02-16       Impact factor: 44.182

View more
  11 in total

Review 1.  Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review.

Authors:  Trina Mitchell; Stéphane Lehéricy; Shannon Y Chiu; Antonio P Strafella; A Jon Stoessl; David E Vaillancourt
Journal:  JAMA Neurol       Date:  2021-10-01       Impact factor: 29.907

Review 2.  Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.

Authors:  Christian U von Linstow; Ziv Gan-Or; Patrik Brundin
Journal:  Transl Neurodegener       Date:  2020-10-16       Impact factor: 8.014

Review 3.  Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases.

Authors:  Heather Wilson; Marios Politis; Eugenii A Rabiner; Lefkos T Middleton
Journal:  Cells       Date:  2020-12-02       Impact factor: 6.600

Review 4.  Genotype-driven therapeutic developments in Parkinson's disease.

Authors:  Jannik Prasuhn; Norbert Brüggemann
Journal:  Mol Med       Date:  2021-04-19       Impact factor: 6.354

Review 5.  Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson's disease.

Authors:  Shigeki Hirano
Journal:  Mol Med       Date:  2021-04-15       Impact factor: 6.354

Review 6.  Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.

Authors:  Sanne K Meles; Wolfgang H Oertel; Klaus L Leenders
Journal:  Mol Med       Date:  2021-09-16       Impact factor: 6.354

7.  Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers.

Authors:  Amgad Droby; Moran Artzi; Hedva Lerman; R Matthew Hutchison; Dafna Ben Bashat; Nurit Omer; Tanya Gurevich; Avi Orr-Urtreger; Batsheva Cohen; Jesse M Cedarbaum; Einat Even Sapir; Nir Giladi; Anat Mirelman; Avner Thaler
Journal:  NPJ Parkinsons Dis       Date:  2022-03-03

Review 8.  Glucocerebrosidase mutations and Parkinson disease.

Authors:  Sophia R L Vieira; Anthony H V Schapira
Journal:  J Neural Transm (Vienna)       Date:  2022-08-06       Impact factor: 3.850

Review 9.  Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers.

Authors:  Elisa Menozzi; Anthony H V Schapira
Journal:  Front Neurol       Date:  2021-06-24       Impact factor: 4.003

10.  Cognition-Related Functional Topographies in Parkinson's Disease: Localized Loss of the Ventral Default Mode Network.

Authors:  Katharina A Schindlbeck; An Vo; Paul J Mattis; Kersten Villringer; Frank Marzinzik; Jochen B Fiebach; David Eidelberg
Journal:  Cereb Cortex       Date:  2021-10-01       Impact factor: 4.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.